At least one tau‐directed treatment (using an anti‐tau antibody) has been reported to reduce CSF levels of P‐tau217 (conference presentation by Michael Fresser at AAT‐AD/PD 2020). This evidence concerns the gene MAPT and Alzheimer disease.